CurrentBlue Cross Blue Shield - TexasPolicy CPCPLABO13

Allergen Testing

Customize your policy alerts

Sign up for Blue Cross Blue Shield - Texas Policy CPCPLABO13 alerts

Get alerted when Policy CPCPLABO13 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Reimbursement and coverage criteria for in‑vitro and related laboratory allergen testing for Blue Cross and Blue Shield of Texas members; applies to providers submitting claims for allergen testing under the plan(s).

Policy Summary

PayerBlue Cross Blue Shield - Texas

PolicyAllergen Testing

Policy CodePolicy CPCPLABO13

Change TypeDocument update following literature review (material and non‑material edits)

Effective DateSep 5, 2025

Last ReviewApr 28, 2025

Next Review Date

Key ActionSubmit accurate coding and documentation that justify selection of allergens based on the patient’s history, physical exam, and environment.

SourceLink

POLICY UPDATE CHANGES

Removed reimbursement item #1 (guidance-only) from the Reimbursement Information section.

Removed Note 1 from the Reimbursement Information section.

Reimbursement Information updated with literature review and reference revisions.

up to 20specific IgE reimbursable/year

annualpediatric re-test

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentBlue Cross Blue Shield - TexasPolicy CPCPLABO13

Allergen Testing

Customize your policy alerts

Sign up for Blue Cross Blue Shield - Texas Policy CPCPLABO13 alerts

Get alerted when Policy CPCPLABO13 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerBlue Cross Blue Shield - Texas

PolicyAllergen Testing

Policy CodePolicy CPCPLABO13

Change TypeDocument update following literature review (material and non‑material edits)

Effective DateSep 5, 2025

Last ReviewApr 28, 2025

Next Review Date

Key ActionSubmit accurate coding and documentation that justify selection of allergens based on the patient’s history, physical exam, and environment.

SourceLink

POLICY UPDATE CHANGES

Removed reimbursement item #1 (guidance-only) from the Reimbursement Information section.

Removed Note 1 from the Reimbursement Information section.

Reimbursement Information updated with literature review and reference revisions.

up to 20specific IgE reimbursable/year

annualpediatric re-test

Coverage and Reimbursement Criteria

Reimbursable testing conditions

Covered or reimbursable when ALL of the following apply

specific_IgE_testing: When limited to allergens chosen for testing based on an individual’s history, physical examination, and environment; specific IgE in–vitro allergy testing may be reimbursable.up to 20 allergens/year

Clinical selection required; limit of up to 20 allergen-specific antibodies per year

total_IgE_indications: Total serum IgE testing may be reimbursable for individuals with moderate to severe asthma OR for individuals with signs or symptoms of allergic bronchopulmonary aspergillosis.

Either clinical indication sufficient

food_allergen_retest_children: To monitor for allergy resolution in children and adolescents with an initial positive food allergen result(s), annual re-testing for the same food allergen(s) may be reimbursable.annual

Only for monitoring resolution in pediatric patients

The policy lists several tests and approaches that are not reimbursable. Specifically, the Antigen Leukocyte Antibody test (ALCAT) is not reimbursable. Additionally, basophil activation flow cytometry and in‑vitro testing of IgG, IgA, IgM, and IgD for allergy evaluation are not reimbursable. The policy also excludes bead‑based epitope assays (for example, VeriMAP Peanut Dx) and qualitative multi‑allergen specific IgE screens that do not identify a specific allergen from reimbursement.

Routine re‑testing for allergies to the same allergens is not reimbursable when performed in the absence of a new clinical presentation. An exception exists for pediatric food allergy monitoring: annual re‑testing for the same food allergen(s) may be reimbursable to monitor for allergy resolution in children and adolescents with an initial positive food allergen result(s).

Procedure Codes and Coding Limits

Procedure codes (document notes list exists but not enumerated)mixed

No codes listed

Specific IgE antibody count

Annual limitUp to 20 allergen-specific IgE antibodies per year

Selection requirementAllergens must be chosen based on the individual’s history, physical examination, and environment

Use-caseApplies to in‑vitro specific IgE (allergen-specific) antibody testing

Provider Requirements and Actions

Denial Risk

Claim Denial Conditions

Claims for tests listed below are not reimbursable. Submit claims only for tests supported by the member's plan and clinical documentation. Providers should confirm coverage in the member's benefit documents prior to billing.

ALCAT (Antigen Leukocyte Antibody Test)
Basophil activation flow cytometry testing
In‑vitro IgG, IgA, IgM, and/or IgD testing
Bead‑based epitope assays (e.g., VeriMAP Peanut Dx)
Qualitative multi‑allergen specific IgE screens that do not identify specific allergens

Documentation Required

Documentation and Coding Accuracy

Providers must submit accurate coding and supporting documentation that justify selection of allergens for testing. Documentation should reflect the individual's history, physical examination, environmental exposures, and clinical indication for testing. Claims are subject to review against industry-standard coding guidelines and plan-specific benefit provisions; incomplete or non‑supportive documentation may result in claim denial or request for additional information.

Background and Scope

Allergen testing in this policy refers primarily to in‑vitro specific IgE testing and measurement of total serum IgE. Specific IgE in‑vitro allergy testing may be reimbursable when limited to allergens chosen based on an individual’s history, physical examination, and environment; the policy permits reimbursement for up to 20 allergen‑specific IgE antibodies per year under those conditions. Measurement of total serum IgE may be reimbursable for individuals with moderate to severe asthma or for those with signs or symptoms suggestive of allergic bronchopulmonary aspergillosis. The policy emphasizes that testing panels should be guided by clinical selection rather than broad unselected screens.

Definitions

Specific IgE in‑vitro allergy testing

DefinitionMeasurement of allergen-specific IgE antibodies in serum (in‑vitro).

Reimbursement allowanceMay be reimbursable when limited to allergens selected based on history, physical exam, and environment

Annual limitUp to 20 allergen-specific antibodies per year when criteria met

Documentation expectationSelection of allergens should be supported by clinical history, exam, and environmental factors

Total serum IgE

DefinitionMeasurement of total serum IgE.

Indications for reimbursement

Policy Update History

2025-04-28policy_updateLatest

Document updated following literature review; reimbursement item #1 (guidance-only) was removed from the Reimbursement Information section; Note 1 was removed; references were revised.